 |
|
Estimating the Fiscal Costs of Osteoporosis in Korea Applying a Public Economic Perspective
Mark P. Connolly, Saswat Panda, Ha Young Kim
J Bone Metab. 2019;26(4):253-261. Published online 2019 Nov 30 DOI: https://doi.org/10.11005/jbm.2019.26.4.253
|
|
Citations to this article as recorded by
 Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea
Seungju Cha, Minjeong Sohn, Hyowon Yang, Eric J. Yeh, Ki-Hyun Baek, Jeonghoon Ha, Hyemin Ku
BMC Musculoskeletal Disorders.2024;[Epub] CrossRef Eleven years secular trend of the initiation of anti-osteoporosis medications and subsequent fractures in Taiwan: From 2008 to 2018
Tsung-Han Yang, Chen-Yu Wang, Shau-Huai Fu, Ding-Cheng Chan, Ho-Min Chen, Jou-Wei Lin, Chun-Feng Huang, Jen-Jia Yang, Chih-Hsing Wu, Jawl-Shan Hwang, Rong-Sen Yang
Journal of the Formosan Medical Association.2023; 122: S36. CrossRef Estimating the future clinical and economic benefits of improving osteoporosis diagnosis and treatment among women in South Korea: a simulation projection model from 2020 to 2040
Micah Jackson, Kyu Hyun Yang, Matthew Gitlin, Zachary Wessler
Archives of Osteoporosis.2021;[Epub] CrossRef
|